Bristol-Myers Squibb BMY
BMY's $91B Celgene deal bets the company on a REVLIMID patent cliff and pipeline requiring 10 blockbusters in 8 years — shareholders should vote no and pursue a standalone Amgen-style transformation.
Thesis
Starboard argues Bristol-Myers' proposed $91B acquisition of Celgene is ill-advised and value-destructive. Management frames the deal as paying ~$15B for Celgene's pipeline, but once cost synergies are properly allocated the implied price is ~$30B — and Celgene must produce 10 blockbusters in 8 years vs. only 3 in the last 15. REVLIMID, 63% of Celgene revenue, faces a 2026 patent cliff that is the largest in pharma history, and 3 of the 5 near-term pipeline products have already been delayed. Even hitting management's aggressive base case earns just a 3% IRR above WACC. The better path: a standalone BMY continuing its 'String of Pearls' strategy funded by ~$37B of cumulative FCF, plus a ~900bps margin improvement modeled on Amgen's 2014-2018 transformation.
SCQA
Bristol-Myers is a mid-sized pharma historically successful under its disciplined 'String of Pearls' strategy of small acquisitions, partnerships and licensing that built a leading immuno-oncology franchise around Opdivo and Eliquis.
Management has abandoned that strategy to buy Celgene for $91B — one of the largest patent cliffs ever (REVLIMID = 63% of revenue, off-patent 2026) — implicitly paying $30B for a pipeline that must produce 10 blockbusters in 8 years.
Shareholders should vote AGAINST the Celgene acquisition, keep Bristol-Myers standalone, continue the 'String of Pearls' approach, and execute an Amgen-style operational transformation to lift EBITDA margins from 36% toward the 48% peer average.
A standalone BMY captures ~900bps of margin upside (36% to 45% pro forma, room toward Amgen's 53%), avoids 2.5x leverage and the REVLIMID overhang, and deploys ~$37B of cumulative FCF into value-accretive bolt-ons.
The three reasons
- 1
BMY is really paying ~$30B for Celgene's pipeline — twice the $15B management implies
- 2
Base case needs 10 blockbusters in 8 years; Celgene produced just 3 in the last 15
- 3
Standalone BMY has ~900bps of EBITDA margin upside using the Amgen playbook
Primary demands
- Vote AGAINST the proposed $91B acquisition of Celgene
- Remain standalone and continue the historically successful 'String of Pearls' bolt-on strategy
- Execute an Amgen-style operational transformation to expand EBITDA margins by ~900bps (COGS, SG&A, R&D)
- Preserve optionality — standalone BMY is of acquirable size and could itself be a target
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Amgen 2014-2018 business transformation (+1,500bps operating margin, +76% stock, Bradway/Meline)
- Shire / Takeda (2018, $81B)
- Allergan / Actavis (2014, $65B, -49% absolute)
- Aventis / Sanofi (2004, $73B, -6%)
- SmithKline Beecham / GlaxoWellcome (2000, $72B, -10%)
- Warner-Lambert / Pfizer (1999, $87B, -32%)
- Jim Cornelius 'String of Pearls' strategy (BMY, 2007)
- Wellington Management's public opposition to the deal (Feb 27, 2019)
Notable slides (6)
Notes
Unusually long (197p) activist deck functioning as a vote-no M&A defense rather than a classic break-up or governance campaign. The rhetorical spine is a founder-quote contradiction: the cover and section 1 lead with former BMY CEO Jim Cornelius — creator of the 'String of Pearls' strategy — so Starboard can argue the current deal betrays the company's own stated philosophy. Core analytical move is the synergy re-allocation (slide 20) that reframes the deal from '$15B for the pipeline' to '$30B', which unlocks the '10 blockbusters in 8 years vs. 3 in 15' attack line on slide 24. Precedent-transaction benchmark (slides 11-13) shows the 5 largest pharma deals all destroyed value on three separate yardsticks — absolute, vs. S&P, vs. pharma index. Amgen analog (slides 152-155) is the 'better path' blueprint with a detailed margin bridge. No stake disclosed in the pages sampled. Campaign outcome: Starboard lost — BMY shareholders approved the deal in April 2019 after ISS/Glass Lewis sided with management and Starboard's own position weakened; deal closed November 2019. Visual craft is functional institutional Starboard house-style (blue/grey palette, bullet-heavy, stacked column charts) — solid but not editorial tier.